Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

NCT00671112 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Stopped Treatment ineffective

Conditions

714leukemia
Lymphoma

Interventions

DRUG: Bortezomib
DRUG: Everolimus

Sponsor

Brian Hill, MD, PhD

Collaborators

[object Object]
[object Object]